Skip to content

Released Aug 14, 2024, before the open

10-Q filed Aug 14, 2024, 45 days after period end · 0001558370-24-012134

Q2 2024 · 10-Q
Revenue$13.47M−61.6% vs Q2 2023+259.5% vs Q1 2024
Net Income-$2.20MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.03N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$2,427,000N/M
Operating Cash Flowderived-$3,610,000N/M
Free Cash Flowderived-$3,782,000N/M
Margins · derived
Operating margin-18.0%−76.2 pt vs Q2 2023
Net margin-16.4%−71.5 pt vs Q2 2023

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Revenue$13.47M$35.08M$8.75M$6.43M
Net Income-$2.20M$19.34M-$5.33M-$11.24M
EPS Diluted-$0.03$0.21-$0.11-$0.25

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR